Several studies have also reported transient activation of ERK1/2 in HER2-overexpressing breast cancer cells by the transactivation of the ErbB2 (HER2) via GDF15-triggered TGFβ receptor-Src activation [27] [28] [31]. This evidence concerns the gene MAPK3 and breast carcinoma.